Key Highlights
- 29% was the rise in orders at IDEX (NYSE:IEX) in the second quarter of 2026, to USD 1,071.6 million, or 28% organic, against sales of USD 920.6 million, up 6%. The July 29, 2026 release implies a book-to-bill ratio of 1.16 (own arithmetic).
- USD 2.32 was adjusted diluted EPS, up 12% from USD 2.07, with adjusted EBITDA of USD 258.3 million and a 28.1% margin, up 70 basis points. Free cash flow was USD 177.0 million, a 103% conversion rate.
- USD 8.70 to USD 8.85 is the raised full-year 2026 adjusted EPS guidance for IDEX (NYSE:IEX), up from USD 8.35 to USD 8.55, with organic sales growth guidance lifted to 5% to 6% from 3% to 4%.
- USD 238.23 was the price of IDEX (NYSE:IEX) on October 16, 2026 intraday, up 0.77%, with a USD 17.56 billion market capitalization, an RSI of 62.1 and a 52-week high of USD 243.80 per published market data.
Price Action and Trading Activity
Per published market data (October 16, 2026 intraday), IDEX (NYSE:IEX) traded at USD 238.23, up 0.77%, on volume of 71,975 shares and relative volume of 0.1x. Turnover was USD 17.15 million (own arithmetic), or 0.10% of market capitalization. The stock is 2.3% below the USD 243.80 high and 48.3% above the USD 160.60 low (own arithmetic). No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. The latest dividend had an October 2 ex-date and is payable October 16, 2026.
Earnings Drivers and Margin Trends
Health and Science Technologies led, with organic sales up 12% and an adjusted EBITDA margin of 28.7%, up 270 basis points, per the Q2 release. Fluid and Metering Technologies grew 1% organically at a 34.8% margin, down 20 basis points, while Fire and Safety and Diversified Products fell 1% organically. Quality of earnings needs a caveat: IEEPA tariff refunds reduced net sales by USD 14.7 million but added USD 0.08 to adjusted EPS, a disclosed non-operating item. Third quarter guidance is organic growth of 5% to 7% and adjusted EPS of USD 2.20 to USD 2.25, below the USD 2.32 reported.
Valuation, Analyst Views and Risks
At USD 238.23 the shares trade at 27.1 times the USD 8.775 midpoint of adjusted EPS guidance (own arithmetic). Per published market data, 12 analysts rate the shares Moderate Buy, with nine Buy, three Hold and no Sell, and an average target of USD 260.73, which is 9.4% above the price (own arithmetic). RBC raised its target to USD 285 with an Outperform rating, while the lowest target is USD 214. Risks include order timing in Health and Science Technologies, flat growth in two of three segments, and a trailing P/E of 34.2.
Where Things Stand
IDEX (NYSE:IEX) trades at a full valuation rather than a discount: the 2.3% gap to the high reflects a 29% rise in orders, a raised guidance range and a 28.1% EBITDA margin, but the shares trade at 27.1 times guided EPS. Orders of USD 1,071.6 million support the guidance, yet growth is concentrated in one segment and the tariff refund added USD 0.08 to adjusted EPS. The next catalyst is third quarter results on October 28, 2026, which will test the multiple against a trailing P/E of 34.2.






Please wait processing your request...